XORTX Therapeutics Inc.

NasdaqCM:XRTX Stock Report

Market Cap: US$4.7m

XORTX Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:XRTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Dec 24BuyUS$1,134Allen DavidoffIndividual1,000US$1.13
02 Oct 24BuyUS$6,889Allen DavidoffIndividual4,300US$1.61
16 Sep 24BuyUS$529Allen DavidoffIndividual300US$1.76
28 Aug 24BuyUS$1,181Allen DavidoffIndividual1,000US$1.18
09 Aug 24BuyUS$3,336Allen DavidoffIndividual2,000US$1.69
05 Jul 24BuyUS$1,807Allen DavidoffIndividual1,000US$1.81
08 Mar 24BuyUS$7,091Anthony GiovinazzoIndividual1,525US$4.65
15 Feb 24BuyUS$22,208Allen DavidoffIndividual10,000US$2.22

Insider Trading Volume

Insider Buying: XRTX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of XRTX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders101,2382.91%
Institutions194,4505.59%
General Public3,185,68791.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 74.2%.

Top Shareholders

Top 12 shareholders own 8.49% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.88%
Armistice Capital LLC
169,790US$227.0k0%0.01%
2.23%
Allen Davidoff
77,557US$103.7k7.33%no data
0.54%
UBS Asset Management AG
18,780US$25.1k0%no data
0.28%
Anthony Giovinazzo
9,625US$12.9k0%no data
0.2%
Paul Van Damme
7,110US$9.5k0%no data
0.2%
James Fairbairn
6,946US$9.3k0%no data
0.099%
National Bank Investments Inc.
3,440US$4.6k0%no data
0.033%
Osaic Wealth, Inc. , Asset Management Arm
1,153US$1.5k0%no data
0.019%
RBC Dominion Securities Inc., Asset Management Arm
672US$898.4-45.2%no data
0.008%
Clearstead Advisors, LLC
277US$370.50%no data
0.0073%
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
254US$339.80%no data
0.0024%
Tower Research Capital Europe Limited
84US$112.20%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 07:47
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XORTX Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Chris ThompsoneResearch Corporation